Enfortumab vedotin
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | DRUG-ENFORTUMAB-VEDOTIN |
|---|---|
| Type | Médicament |
| Alias | ASG-22MEPâdcevenfortumab vedotin-ejfvЕнфортумаб ведотин |
| État | reviewed 2026-04-27 | pending_clinical_signoff |
| Maladies | DIS-UROTHELIAL |
| Sources | SRC-EAU-BLADDER-2024 SRC-NCCN-BLADDER-2025 |
Faits sur les drogues
| Catégorie | Conjugué anticorps-médicament ciblés contre la nectine-4 (charge utile de l'AAMM) |
|---|---|
| Mécanisme | Fully human anti-Nectin-4 IgG1κ monoclonal antibody (AGS-22M6) conjugated via a protease-cleavable maleimidocaproyl-valine- citrulline-PAB linker to monomethyl auristatin E (MMAE), a potent microtubule-disrupting cytotoxic payload (drug-to-antibody ratio ~3.8). Nectin-4 (PVRL4) is highly expressed in urothelial carcinoma (>95% of mUC cases), with limited normal-tissue expression (skin keratinocytes, salivary gland — accounting for characteristic skin and ocular AEs). After antigen binding the ADC is internalized; lysosomal cleavage releases MMAE, which binds tubulin and induces G2/M arrest and apoptosis. Pivotal EV-302 (1L locally advanced / metastatic urothelial carcinoma: enfortumab vedotin + pembrolizumab vs platinum-based chemo): mPFS 12.5 vs 6.3 mo HR 0.45, mOS 31.5 vs 16.1 mo HR 0.47 — first combination to surpass platinum chemo as 1L mUC standard, paradigm-shifting; FDA full appr... |
| Dose typique | 1.25 mg/kg (capped at 125 mg per dose for patients ≥100 kg) IV over 30 minutes on Days 1, 8, 15 of each 28-day cycle. With or without pembrolizumab 200 mg IV q3w (per EV-302; pembrolizumab given Day 1 of each pembro cycle). Continue until disease progression / unacceptable toxicity. Dose level -1 = 1.0 mg/kg; -2 = 0.75 mg/kg; -3 = 0.5 mg/kg; permanent discontinuation if recurrent G3-4 at -3. Hold for G3-4 skin toxicity, G3-4 hyperglycemia, G3-4 peripheral neuropathy, G3-4 ocular toxicity, pneumonitis, severe infusion reaction. Renal: no formal adjustment for CrCl ≥30; not studied in severe renal impairment. Hepatic: avoid in moderate-severe hepatic impairment (no PK data). |
| Ukraine enregistrée | Faux |
| NSZU remboursé | Faux |
| Ukraine vérifiée pour la dernière fois | 2026-04-27 |
Avertissements
- Effets indésirables cutanés graves et fatals (en boîte) — y compris SJS / TEN / DRESS / SCAR; peuvent être mortaux; mandater immédiatement la suspension pour toute nouvelle réaction cutanée pire que l'éruption maculopapulaire, consultation dermatologique, et arrêt permanent pour les réactions SJs / TE / G4
Notes
EV-302 (NEJM 2024 Powles): paradigm-shifting trial that moved enfortumab+pembrolizumab to 1L mUC SoC, displacing platinum-based chemo. mOS doubling (31.5 vs 16.1 mo) is among the largest ever reported in mUC. Hyperglycemia is the signal AE — monitor fasting glucose weekly first 4 weeks then with each cycle, especially in diabetic / pre-diabetic / obese patients (BMI >30); proactive metformin and insulin adjustment. Mandatory baseline + ongoing ophthalmologic exam; lubricating drops continuously; corticosteroid drops for keratitis. Skin toxicity escalation algorithm: hold and dermatology consult for any new rash with pustules, target lesions, or mucosal involvement (SJS suspicion); permanent discontinuation for SJS/TEN. Counsel patients on neuropathy onset (gloves/socks early symptom). UA access via EAP / cross-border / self-pay only — not on НСЗУ. EV-302 access pathway is the dominant 1L mUC standard in EU centers via "Лікування за кордоном" (наказ МОЗ 988).
Utilisé par
Protocole thérapeutique
REG-EV-MONO-UROTHELIAL- Enfortumab vedotin monothérapie (carcinome urothélial)REG-EV-PEMBRO-UROTHELIAL- Enfortumab vedotin + pembrolizumab (métastatique urothéliale, 1L)